DPYD variants to predict 5-FU toxicity: The ultimate proof

Journal of the National Cancer Institute

Volumn 106, Issue 12, 2014, Pages

  Innocenti, Federico ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DIHYDROPYRIMIDINE DEHYDROGENASE;

CANCER PATIENT; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DPYD GENE; DRUG SAFETY; EDITORIAL; GENE; GENETIC VARIABILITY; GENOTYPE; HERITABILITY; HETEROZYGOSITY; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; COLONIC NEOPLASMS; FEMALE; GENETICS; MALE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84922394947     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju351     Document Type: Editorial

References (14)

1. Berger R, Stoker-de Vries SA, Wadman SK, et al. Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism. Clin Chim Acta. 1984;141(2-3):227-234.
2. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest. 1988;81(1):47-51.
3. Lee et al.
4. Schilsky RL. Wither the cooperative groups? J Clin Oncol. 2014;32(3):251-254.
5. Gillis NK, Innocenti F. Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues. Clin Pharmacol Ther. 2014; In press.
6. Schwab M, Zanger UM, Marx C, et al. German 5-FU Toxicity Study Group. Role of genetic and nongenetic factors for fluorouracil treatmentrelated severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008;26(13):2131-2138.
7. Morel A, Boisdron-Celle M, Fey L, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther. 2006;5(11):2895-2904.
8. Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32(10):1031-1039.
9. Church D, Kerr R, Domingo E, et al. 'Toxgnostics': an unmet need in cancer medicine. Nat Rev Cancer. 2014;14(6):440-445.
10. Gillis NK, Patel JN, Innocenti F. Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther. 2014;95(3):269-280.
11. Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94(6):640-645.
12. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662-673.
13. Innocenti F, Schilsky RL, Ramírez J, et al. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014;32(22):2328-2334.
14. Toffoli G, Cecchin E, Gasparini G, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(5):866-871.